A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
A prostate cancer test using protein and genetic markers improves diagnosis accuracy and reduces unnecessary procedures across ethnic groups.
Read More
A study warns that transgender women on hormone therapy may have artificially low PSA levels, potentially delaying prostate cancer diagnosis.
Read More
The new urine-based test aims to differentiate between slow-growing and aggressive forms of prostate cancer.
Read More
A study found an active surveillance blood test for prostate cancer could predict whether a patient had indolent or aggressive disease.
Read More
A study investigating a single invitation to a PSA blood test to screen for prostate cancer found it had a small impact on reducing deaths.
Read More
MRI of the prostate, combined with a blood test, can help find if a prostate lesion is clinically significant cancer, new research suggests.
Read More
Researchers developed a deep-learning model to improve the 3D segmentation of glandular tissue structures for prostate cancer assessment.
Read More
AI has helped scientists reveal a new form of aggressive prostate cancer which could revolutionize how the disease is diagnosed in the future.Â
Read More
Oncobiomix says it will use Limmi’s Disease Insights Platform to power their AI models for predicting prostate cancer risk.
Read More
Pathologists at OSUCCC-James have been evaluating an AI algorithm for the past year. The results are extremely promising.
Read More
A new study has found that rectal examination has no advantages over the PSA blood test for detecting prostate cancer.
Read More
Researchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma.
Read More
ArteraAI says the CMS decided on the payment rate for the ArteraAI Prostate Test, a clinical diagnostic laboratory test for prostate cancer.
Read More
UCLA Researchers have received a five-year, $3 million grant to develop AI that can detect and predict aggressive prostate cancer.
Read More
Men with biomarker HSD3B1 may exhibit resistance to combined radiation and hormone therapy for prostate cancer.Â
Read More